Vicore Pharma develops novel pharmaceutical drugs with capabilities in stimulating the AT₂receptor and thereby address large unmet clinical needs in cardiovascular disease and other conditions where healing can take place with the help of AT₂stimulation. Based on its proprietary and documented substances and under the expert leadership of Vita Nova Ventures and strategic R&D partners the company shall develop and market its patents and know-how. Our vision is for the AT₂concept to be a leading pharmaceutical principle and as such enhance the life of millions of sufferers of cardiovascular disease and other diseases where AT₂stimulation has a beneficial effect on clinical outcome.